These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29379493)

  • 1. Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.
    Almagro JC; Daniels-Wells TR; Perez-Tapia SM; Penichet ML
    Front Immunol; 2017; 8():1751. PubMed ID: 29379493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage display-derived human antibodies in clinical development and therapy.
    Frenzel A; Schirrmann T; Hust M
    MAbs; 2016 Oct; 8(7):1177-1194. PubMed ID: 27416017
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    André AS; Moutinho I; Dias JNR; Aires-da-Silva F
    Front Microbiol; 2022; 13():962124. PubMed ID: 36225354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of Recombinant Human Antibodies.
    Tomszak F; Weber S; Zantow J; Schirrmann T; Hust M; Frenzel A
    Adv Exp Med Biol; 2016; 917():23-54. PubMed ID: 27236551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The promise of bispecific antibodies.
    Kufer P; Lutterbüse R; Baeuerle PA
    Discov Med; 2004 Oct; 4(23):325-32. PubMed ID: 20704969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular engineering and design of therapeutic antibodies.
    Presta LG
    Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview on the use of therapeutic antibodies in drug discovery.
    Roguska M; Kaymakcalan Z; Salfeld J
    Curr Protoc Pharmacol; 2005 Jan; Chapter 9():Unit 9.7. PubMed ID: 22294129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Engineering.
    Lo KM; Leger O; Hock B
    Microbiol Spectr; 2014 Feb; 2(1):AID-0007-2012. PubMed ID: 26082127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage Display Libraries for Antibody Therapeutic Discovery and Development.
    Almagro JC; Pedraza-Escalona M; Arrieta HI; Pérez-Tapia SM
    Antibodies (Basel); 2019 Aug; 8(3):. PubMed ID: 31544850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Historical development of monoclonal antibody therapeutics.
    Nissim A; Chernajovsky Y
    Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform.
    Foltz IN; Gunasekaran K; King CT
    Immunol Rev; 2016 Mar; 270(1):51-64. PubMed ID: 26864104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering therapeutic monoclonal antibodies.
    Liu XY; Pop LM; Vitetta ES
    Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies and therapeutics].
    Desgranges C
    Pathol Biol (Paris); 2004 Jul; 52(6):351-64. PubMed ID: 15261379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fully human antibodies from transgenic mouse and phage display platforms.
    Lonberg N
    Curr Opin Immunol; 2008 Aug; 20(4):450-9. PubMed ID: 18606226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy.
    Zhao A; Tohidkia MR; Siegel DL; Coukos G; Omidi Y
    Crit Rev Biotechnol; 2016; 36(2):276-89. PubMed ID: 25394539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leveraging SBDD in protein therapeutic development: antibody engineering.
    Gilliland GL; Luo J; Vafa O; Almagro JC
    Methods Mol Biol; 2012; 841():321-49. PubMed ID: 22222459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA.
    Larrick JW; Alfenito MR; Scott JK; Parren PW; Burton DR; Bradbury AR; Lemere CA; Messer A; Huston JS; Carter PJ; Veldman T; Chester KA; Schuurman J; Adams GP; Reichert JM
    MAbs; 2016; 8(8):1425-1434. PubMed ID: 27557809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.